Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Bioadaptives (BDPT) Cost of Revenue (2019 - 2025)

Historic Cost of Revenue for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to $781.0.

  • Bioadaptives' Cost of Revenue changed N/A to $781.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2937.0, marking a year-over-year decrease of 7765.01%. This contributed to the annual value of $8639.0 for FY2024, which is 5131.86% down from last year.
  • Latest data reveals that Bioadaptives reported Cost of Revenue of $781.0 as of Q3 2025.
  • Bioadaptives' 5-year Cost of Revenue high stood at $10999.0 for Q3 2023, and its period low was $246.0 during Q2 2024.
  • For the 5-year period, Bioadaptives' Cost of Revenue averaged around $3065.2, with its median value being $2198.0 (2021).
  • As far as peak fluctuations go, Bioadaptives' Cost of Revenue tumbled by 7102.47% in 2024, and later surged by 77642.28% in 2025.
  • Quarter analysis of 5 years shows Bioadaptives' Cost of Revenue stood at $2709.0 in 2021, then grew by 9.04% to $2954.0 in 2022, then soared by 52.4% to $4502.0 in 2023, then plummeted by 94.54% to $246.0 in 2024, then soared by 217.48% to $781.0 in 2025.
  • Its Cost of Revenue was $781.0 in Q3 2025, compared to $2156.0 in Q2 2025 and $246.0 in Q2 2024.